Moving the Needle in Neovascular Age-related Macular Degeneration Treatment

0.50 CME
0.50 ABO MOC
$0 FEE
Moving the Needle in Neovascular Age-related Macular Degeneration Treatment


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Allergan, Inc.

Activity Description

Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases, offering patients delayed or arrested disease progression, with the possibility of regaining lost vision. The treatment of patients with neovascular age-related macular degeneration (nAMD) has been revolutionized by intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. However, long-term extensions of major clinical trials have not demonstrated consistent success in maintaining the dramatic vision gains obtained initially, particularly when as-needed dosing was used. Fixed-interval or treat-and-extend protocols, which generally use more frequent injections, have had success in maintaining vision gains. Further, newer protocols that allow for longer intervals between treatments are now available and hold promise in lessening treatment burden. In this educational activity, expert faculty discuss the latest evidence-based medicine regarding treatment protocols for patients with nAMD.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with neovascular age-related macular degeneration (nAMD).

Learning Objective(s)

Upon successful completion of this activity, participants should be better able to:

  • Assess clinical trial outcomes achieved with anti-VEGF agents in nAMD and the extent the trial results reflect those achieved in real-world practice.
  • Evaluate emerging and new agents, as well as delivery techniques that require less frequent administration, to optimize visual results in patients with nAMD.

Activity Chair

Peter K. Kaiser, MD
Chaney Family Endowed Chair in Ophthalmology
Research Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
Cleveland, OH


Michael S. Ip, MD
Professor of Ophthalmology
Medical Director, Doheny Image Reading Center
Doheny Eye Institute
University of California – Los Angeles
Pasadena, CA


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.

This enduring material is approved for 1 year from the date of original release, April 24, 2020, through April 23, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Activity Chair and Faculty report the following relationship(s)

Michael S. Ip, MD
Consulting Fee: Allegro, Allergan, Amgen, BioTime, Boehringer Ingelheim, Clearside, Genentech, Novartis, Regenxbio, ThromboGenics

Peter K. Kaiser, MD
Consulting Fee: Aerie, Aerpio, Alcon, Allegro, Allergan, Bausch + Lomb, Bayer, Biogen Idec, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Eyevensys, Formycon/BioEq GmbH, Galecto Biotech, Galimedix, Hospira, Irenix, jCyte, Kala, Kodiak, NGM Biopharmaceuticals, Novartis, Ocugenix, Omeros, Opthea, Oxurion (ThromboGenics), Regeneron, Regenxbio, Retinal Sciences, Roivant, Santen, SciFluor, Shire, Spark Therapeutics, Stealth Biotherapeutics, Verena (Digisight), Zeiss

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at